RxDoctor Payments Data

Radu Hagau, MD

Cardiovascular Disease · Mason City, IANPI 1073742144

Payments from drug & device makers

What this record shows

21 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 32.9% of the total. Reporting peaked in 2021 at $1,922 and has fallen 68.1% since, to $613 in 2025.

$3,085in general payments, 2019–2025

Across 69 payments — averaging $44.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$1K
  • GE HealthCare$908
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$166
  • Edwards Lifesciences$133
  • Novartis$107
  • AstraZeneca$103
  • plus $654 from 15 others

What the payments were for

  • Travel & lodging$1,81059%
  • Food & beverage$1,27541%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 70th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$122,709
Medicare patients
970
Services billed
1,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$214,180
XareltoRivaroxaban45$45,134
BrilintaTicagrelor14$15,715
Praluent PenAlirocumab28$15,539
JardianceEmpagliflozin13$11,255
Metoprolol Succinate640$10,098
Repatha SureclickEvolocumab16$8,861
Isosorbide Mononitrate ErIsosorbide Mononitrate281$4,633
Atorvastatin Calcium434$3,925
Dofetilide20$3,794
Rosuvastatin Calcium275$3,598
Torsemide212$3,412
Ranolazine ErRanolazine18$3,025
ClopidogrelClopidogrel Bisulfate191$2,337
Amiodarone Hcl37$1,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$214,180218 claims
Johnson & JohnsonXarelto$33$45,13445 claims
AstraZenecaBrilinta$103$15,71514 claims
Boehringer IngelheimJardiance$85$11,25513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →